Physician profile
Jeffrey W Cloud
NPI 1518179126
$3,298.21
in general payments reported to CMS, 2019-2025
21 companies · $551 in 2025
The $551 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $231 · 2021: $729 · 2022: $781 · 2023: $326 · 2024: $537 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357 · Education: $55.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.11 |
| Education | $55.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,119.17 | 2020-2025 | Lumigan, Alphagan P, Rinvoq |
| Braintree Laboratories, INC. | $645.77 | 2020-2022 | |
| Gilead Sciences, INC. | $355.82 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $260.46 | 2020-2025 | Entyvio |
| Genzyme Corporation | $195.71 | 2022-2024 | |
| Pfizer INC. | $145.00 | 2019 | |
| Madrigal Pharmaceuticals | $89.77 | 2024 | Resmetirom, Rezdiffra |
| Aimmune Therapeutics, INC. | $61.54 | 2024-2025 | Zenpep |
| Fujifilm Healthcare Americas Corporation | $56.88 | 2025 | |
| Celgene Corporation | $54.41 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $50.12 | 2025 | Sucraid |
| Janssen Biotech, INC. | $48.78 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $43.75 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $41.83 | 2024-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $22.23 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.79 | 2024 | Xifaxan |
| Olympus America INC. | $21.61 | 2024 | Endoclot Phs |
| Janssen Pharmaceuticals, INC | $19.76 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Merck Sharp & Dohme LLC | $14.02 | 2022 | |
| Intercept Pharmaceuticals, INC. | $13.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cloud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.